<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857892</url>
  </required_header>
  <id_info>
    <org_study_id>213055</org_study_id>
    <nct_id>NCT04857892</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants</brief_title>
  <official_title>A Two-Part, Randomized, Open-Label, Single Dose, Crossover Clinical Study to Assess the Relative Bioavailability of Fixed-Dose Combinations of GSK3640254 and Dolutegravir and to Assess the Effect of Food on the Select Fixed Dose Combination of GSK3640254 and Dolutegravir in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two part study to compare the relative bioavailability (BA) of 2 fixed dose&#xD;
      combinations (FDCs) of GSK3640254/DTG with GSK3640254 and DTG administered together as single&#xD;
      agents (Part 1) and to assess the effect of food on the pharmacokinetic (PK) of the selected&#xD;
      FDC of GSK3640254/DTG (Part 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Actual">September 10, 2021</completion_date>
  <primary_completion_date type="Actual">September 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a 2-part crossover study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Parts 1 and 2: Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC[0-inf]) for GSK3640254 and DTG</measure>
    <time_frame>Up to Day 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Area under the plasma concentration-time curve from time 0 to time t (AUC[0-t]) for GSK3640254 and DTG</measure>
    <time_frame>Up to Day 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Maximum observed concentration (Cmax) for GSK3640254 and DTG</measure>
    <time_frame>Up to Day 31</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Number of participants with adverse events (AEs) and Serious adverse events (SAEs)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, absolute neutrophil count and platelet count (Giga cells per liter)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of Hematology Parameter: Hemoglobin (Grams per Liter)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of Hematology Parameter: Mean Corpuscular Volume (MCV) (Femtoliters)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of Hematology Parameter: Red blood cell count (RBC) count (Trillion cells per liter)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of Hematology Parameter: Hematocrit (Proportion of red blood cells in blood)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of Hematology Parameter: Mean corpuscular hemoglobin (picograms)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Absolute neutrophil count and platelet count (Giga cells per liter)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in hematology Parameter: Hemoglobin (Grams per Liter)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in hematology Parameter: MCV (Femtoliters)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in hematology Parameter: RBC count (Trillion cells per liter)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Hematology Parameter: Hematocrit (Proportion of red blood cells in blood)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Hematology Parameter: Mean corpuscular hemoglobin (picograms)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2 Absolute values for Alanine Amino Transferase (ALT),Alkaline Phosphatase (ALP),Aspartate Amino Transferase (AST),Gamma Glutamyl Transferase (GGT),Lactate dehydrogenase, Creatinine phosphokinase(International units per Liter)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of clinical chemistry parameters: Calcium, carbon-dioxide (CO2), chloride, glucose, potassium, sodium, Blood urea nitrogen, phosphorus, Triglycerides, total cholesterol, and Anion gap (Millimole per Liter)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of clinical chemistry parameters: Serum lipase, serum amylase (Units per Liter)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of clinical chemistry parameters: Albumin, Globulin and Total protein (grams per liter)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of clinical chemistry parameters: Creatinine, direct bilirubin, total bilirubin, uric acid (micromoles per liter)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in clinical chemistry parameters: ALT, ALP, AST, GGT, Lactate dehydrogenase, Creatinine phosphokinase (International units per Liter)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in clinical chemistry parameters: Calcium, CO2, chloride, glucose, potassium, sodium, Blood urea nitrogen, phosphorus, Triglycerides, total cholesterol, and Anion gap (Millimoles per Liter)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in clinical chemistry parameters: Serum lipase, serum amylase (Units per Liter)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in clinical chemistry parameters: Albumin, Globulin and Total protein (grams per liter)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in clinical chemistry parameters: Creatinine, direct bilirubin, total bilirubin, uric acid (micromoles per liter)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of Urinalysis parameter: Urine Specific Gravity</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of Urinalysis parameter: Urine potential of hydrogen (pH)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of Urinalysis parameter: Glucose</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Absolute values of Urinalysis parameter: Protein</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Absolute values of Urinalysis parameter: Blood</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Absolute values of Urinalysis parameter: Ketones</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Absolute values of Urinalysis parameters: Bilirubin, Nitrite (Milligrams per deciliter)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of Urinalysis parameter: Leukocyte esterase</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Urinalysis parameter: Urine Specific Gravity</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Urinalysis parameter: Urine pH</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Urinalysis parameter: Glucose</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Urinalysis parameter: Protein</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Urinalysis parameter: Blood</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Urinalysis parameter: Ketones</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Urinalysis parameters: Bilirubin, Nitrite (Milligrams per deciliter)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Urinalysis parameter: Leukocyte esterase</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of Electrocardiogram (ECG) parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) (milliseconds)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in ECG parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval (milliseconds)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2:Absolute values of vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) (millimeters of mercury)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of vital signs: Pulse rate</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of vital signs: Temperature</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Absolute values of vital signs : Respiratory rate</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in vital signs: DBP and SBP (millimeters of mercury)</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in vital signs : Pulse rate</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in vital signs: Temperature</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in vital signs: Respiratory rate</measure>
    <time_frame>Baseline and up to Day 31</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Part 1 : Treatment sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of GSK3640254 25 milligrams (mg) (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A) in Period 1, followed by a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 2. In Period 3, participants will receive a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 : Treatment sequence BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 1, followed by a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 : Treatment sequence CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in period 1, followed by a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 : Treatment sequence DE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions (Treatment D) in Period 1 followed by a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions (Treatment E) in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 : Treatment sequence ED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions (Treatment E) in Period 1 followed by a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions (Treatment D) in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3640254</intervention_name>
    <description>GSK3640254 will be administered via oral route.</description>
    <arm_group_label>Part 1 : Treatment sequence ABC</arm_group_label>
    <arm_group_label>Part 1 : Treatment sequence BCA</arm_group_label>
    <arm_group_label>Part 1 : Treatment sequence CAB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG</intervention_name>
    <description>DTG will be administered via oral route.</description>
    <arm_group_label>Part 1 : Treatment sequence ABC</arm_group_label>
    <arm_group_label>Part 1 : Treatment sequence BCA</arm_group_label>
    <arm_group_label>Part 1 : Treatment sequence CAB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3640254/DTG</intervention_name>
    <description>GSK3640254/DTG will be administered via oral route.</description>
    <arm_group_label>Part 1 : Treatment sequence ABC</arm_group_label>
    <arm_group_label>Part 1 : Treatment sequence BCA</arm_group_label>
    <arm_group_label>Part 1 : Treatment sequence CAB</arm_group_label>
    <arm_group_label>Part 2 : Treatment sequence DE</arm_group_label>
    <arm_group_label>Part 2 : Treatment sequence ED</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 to 65 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, laboratory tests, and cardiac monitoring&#xD;
             (history and ECG).&#xD;
&#xD;
          -  Participants capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or chronic history of liver disease or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  A pre-existing condition interfering with normal gastro intestinal anatomy or motility&#xD;
             (for example [e.g.], gastroesophageal reflux disease, gastric ulcers, gastritis) or&#xD;
             hepatic and/or renal function that could interfere with the absorption, metabolism,&#xD;
             and/or excretion of the study intervention or render the participant unable to take&#xD;
             oral study intervention.&#xD;
&#xD;
          -  Prior cholecystectomy surgery (prior appendectomy is acceptable).&#xD;
&#xD;
          -  Clinically significant illness, including viral syndromes within 3 weeks of dosing.&#xD;
&#xD;
          -  Participant with known or suspected active Coronavirus disease (COVID)-19 infection or&#xD;
             contact with an individual with known COVID-19, within 14 days of study enrollment.&#xD;
&#xD;
          -  Current enrollment or past participation within the last 30 days before signing of&#xD;
             consent in any other clinical study involving an investigational study intervention&#xD;
             (including an investigational COVID vaccine) or any other type of medical research.&#xD;
&#xD;
          -  Prior exposure to GSK3640254 or prior intolerance to DTG in this or another clinical&#xD;
             study.&#xD;
&#xD;
          -  Any positive (abnormal) response confirmed by the investigator on a screening&#xD;
             clinician- or qualified designee-administered Columbia Suicide Severity Rating Scale&#xD;
             (C-SSRS).&#xD;
&#xD;
          -  Any significant arrhythmia or ECG finding (e.g., prior myocardial infarction in the&#xD;
             past 3 months, symptomatic bradycardia, non-sustained or sustained atrial arrhythmias,&#xD;
             non-sustained or sustained ventricular tachycardia, any degree of atrioventricular&#xD;
             block, or conduction abnormality) which, in the opinion of the investigator or ViiV&#xD;
             Healthcare (VH)/GlaxoSmithKline (GSK) medical monitor, will interfere with the safety&#xD;
             for the individual participant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dolutegravir</keyword>
  <keyword>GSK3640254</keyword>
  <keyword>Fixed Dose Combinations</keyword>
  <keyword>Bioavailability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

